GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC), a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines, today announced financial results for the fourth quarter and year ended December 31, 2006. For the year ended December 31, 2006, the company reported a net loss of $19.3 million, or $0.30 per share, compared with a net loss of $14.0 million, or $0.24 per share for the year ended December 31, 2005. GenVec ended the year with $34.4 million in cash and total investments.
